{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:11:22Z","timestamp":1769065882045,"version":"3.49.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Loss of a whole chromosome 5 or a deletion of the long arm, del(5q), is a recurring abnormality in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). To identify a leukemia-related gene on chromosome 5, we previously delineated a 970-kb segment of 5q31 that is deleted in all patients examined, and prepared a transcript map of this region. EGR1 is a candidate tumor suppressor gene within the commonly deleted segment of 5q, and encodes a zinc finger transcription factor. To test the hypothesis that loss of function of Egr1 is an initiating event in the pathogenesis of AML\/MDS, Egr1-deficient mice were treated with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce secondary cooperating mutations. Egr1+\/\u2212 and Egr1\u2212\/\u2212 mice treated with ENU developed immature T-cell lymphomas (CD4+, CD8+) or a myeloproliferative disorder (MPD) at increased rates and with shorter latencies than that of wild-type littermates. The MPD was characterized by an elevated white blood cell count, anemia, and thrombocytopenia with ineffective erythropoiesis. Biallelic mutations of Egr1 were not observed in MPDs in Egr1+\/\u2212 mice. Our data suggest that haploinsufficiency for Egr1 plays a role in murine leukemogenesis, and in the development of AML\/MDS characterized by abnormalities of chromosome 5.<\/jats:p>","DOI":"10.1182\/blood-2007-01-068809","type":"journal-article","created":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T00:44:05Z","timestamp":1176165845000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":180,"title":["Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders"],"prefix":"10.1182","volume":"110","author":[{"given":"John M.","family":"Joslin","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology and the Cancer Research Center, University of Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Fernald","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology and the Cancer Research Center, University of Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thelma R.","family":"Tennant","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology and the Cancer Research Center, University of Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology and the Cancer Research Center, University of Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Kogan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California at San Francisco;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Anastasi","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Crispino","sequence":"additional","affiliation":[{"name":"Ben May Department for Cancer Research, University of Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Le Beau","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology and the Cancer Research Center, University of Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111711391155400_B1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-8588(05)70340-3","article-title":"Therapy-related myeloid leukemia.","volume":"10","author":"Thirman","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111711391155400_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/geno.2000.6414","article-title":"Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).","volume":"71","author":"Lai","year":"2001","journal-title":"Genomics"},{"key":"2019111711391155400_B3","doi-asserted-by":"crossref","first-page":"3443a","DOI":"10.1182\/blood.V106.11.3443.3443","article-title":"Comprehensive promoter methylation analysis of genes on 5q31.1 in MDS and AML [abstract].","volume":"106","author":"Oki","year":"2005","journal-title":"Blood"},{"key":"2019111711391155400_B4","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1074\/jbc.274.7.4400","article-title":"The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.","volume":"274","author":"Liu","year":"1999","journal-title":"J Biol Chem"},{"key":"2019111711391155400_B5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1083\/jcb.133.1.211","article-title":"UV activates growth factor receptors via reactive oxygen intermediates.","volume":"133","author":"Huang","year":"1996","journal-title":"J Cell Biol"},{"key":"2019111711391155400_B6","first-page":"3","article-title":"Suppression of growth and transformation and induction of apoptosis by EGR-1.","volume":"5","author":"Liu","year":"1998","journal-title":"Cancer Gene Ther"},{"key":"2019111711391155400_B7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.3672127","article-title":"A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.","volume":"238","author":"Milbrandt","year":"1987","journal-title":"Science"},{"key":"2019111711391155400_B8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0092-8674(88)90485-0","article-title":"A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization.","volume":"53","author":"Sukhatme","year":"1988","journal-title":"Cell"},{"key":"2019111711391155400_B9","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1073\/pnas.2628034100","article-title":"Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence.","volume":"100","author":"Krones-Herzig","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111711391155400_B10","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/0008-5472.CAN-04-3742","article-title":"Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53.","volume":"65","author":"Krones-Herzig","year":"2005","journal-title":"Cancer Res"},{"key":"2019111711391155400_B11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cncr.21262","article-title":"Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma.","volume":"104","author":"Ronski","year":"2005","journal-title":"Cancer"},{"key":"2019111711391155400_B12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2005.08.127","article-title":"EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer.","volume":"23","author":"Ferraro","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111711391155400_B13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.cgt.7700896","article-title":"The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.","volume":"13","author":"Baron","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"2019111711391155400_B14","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1074\/jbc.270.17.9971","article-title":"Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A.","volume":"270","author":"Lee","year":"1995","journal-title":"J Biol Chem"},{"key":"2019111711391155400_B15","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V99.8.2985","article-title":"Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia.","volume":"99","author":"Le Beau","year":"2002","journal-title":"Blood"},{"key":"2019111711391155400_B16","doi-asserted-by":"crossref","DOI":"10.1385\/0-89603-482-8:53","volume-title":"Gene Mapping by FISH","author":"Espinosa","year":"1996"},{"key":"2019111711391155400_B17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/(SICI)1098-2264(199711)20:3<282::AID-GCC9>3.0.CO;2-Z","article-title":"dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.","volume":"20","author":"Wang","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111711391155400_B18","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1158\/0008-5472.CAN-05-3404","article-title":"Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice.","volume":"66","author":"Fenske","year":"2006","journal-title":"Cancer Res"},{"key":"2019111711391155400_B19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/13776","article-title":"The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia.","volume":"23","author":"Castilla","year":"1999","journal-title":"Nat Genet"},{"key":"2019111711391155400_B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1535-6108(02)00016-8","article-title":"Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.","volume":"1","author":"Higuchi","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111711391155400_B21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.emboj.7600521","article-title":"Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.","volume":"24","author":"Wang","year":"2005","journal-title":"EMBO J"},{"key":"2019111711391155400_B22","doi-asserted-by":"crossref","first-page":"10398","DOI":"10.1073\/pnas.171321298","article-title":"AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.","volume":"98","author":"Yuan","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111711391155400_B23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00335-004-2379-z","article-title":"A gene-driven ENU-based approach to generating an allelic series in any gene.","volume":"15","author":"Quwailid","year":"2004","journal-title":"Mamm Genome"},{"key":"2019111711391155400_B24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2019111711391155400_B25","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/sj.leu.2404009","article-title":"Mutations of genes in the receptor tyrosine kinase (RTK)\/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.","volume":"19","author":"Christiansen","year":"2005","journal-title":"Leukemia"},{"key":"2019111711391155400_B26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111711391155400_B27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/bcmd.1996.0110","article-title":"N-ras mutations in radiation-induced murine leukemic cells.","volume":"22","author":"Rithidech","year":"1996","journal-title":"Blood Cells Mol Dis"},{"key":"2019111711391155400_B28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/0955300031000139371","article-title":"Genetic susceptibility to thymic lymphomas and K-ras gene mutation in mice after exposure to X-rays and N-ethyl-N-nitrosourea.","volume":"79","author":"Shimada","year":"2003","journal-title":"Int J Radiat Biol"},{"key":"2019111711391155400_B29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2006.06.052","article-title":"Multilineage transcriptional priming and determination of alternate hematopoietic cell fates.","volume":"126","author":"Laslo","year":"2006","journal-title":"Cell"},{"key":"2019111711391155400_B30","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1038\/sj.onc.1202721","article-title":"An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation.","volume":"18","author":"Gibbons","year":"1999","journal-title":"Oncogene"},{"key":"2019111711391155400_B31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ijc.2910410517","article-title":"Further studies on chromosome 15 trisomy in murine T-cell lymphomas: mapping of the relevant chromosome segment.","volume":"41","author":"Silva","year":"1988","journal-title":"Int J Cancer"},{"key":"2019111711391155400_B32","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood-2003-01-0155","article-title":"Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia.","volume":"102","author":"Le Beau","year":"2003","journal-title":"Blood"},{"key":"2019111711391155400_B33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V100.1.238","article-title":"Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.","volume":"100","author":"Kogan","year":"2002","journal-title":"Blood"},{"key":"2019111711391155400_B34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.emboj.7600987","article-title":"Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras.","volume":"25","author":"Shin","year":"2006","journal-title":"EMBO J"},{"key":"2019111711391155400_B35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/2\/719\/1293456\/zh801407000719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/2\/719\/1293456\/zh801407000719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T09:33:42Z","timestamp":1587461622000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/2\/719\/22975\/Haploinsufficiency-of-EGR1-a-candidate-gene-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-01-068809","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}